Tauopathy Comparison Matrix

Migration, Crosslink

📖

Tauopathy Comparison Matrix

active

wiki page Created: 2026-04-02T07:20:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-tauopathy-comparison

📖 Wiki Page

disease1790 wordssynced 2026-04-02

Tauopathy Comparison Matrix

Overview

This page provides a comprehensive comparative analysis of the major tauopathies—Alzheimer's Disease (AD), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), and Frontotemporal Lobar Degeneration with tau pathology (FTLD-tau). These disorders share the common feature of abnormal tau protein accumulation but differ significantly in their clinical presentations, anatomical distributions, tau isoforms involved, and genetic risk factors[@goedert2022].

flowchart TD subgraph Tauopathies ["Major Tauopathies"] AD["Alzheimer's Disease"] CBD["Corticobasal Degeneration"] PSP["Progressive Supranuclear Palsy"] FTLD["FTLD-tau"] end subgraph CommonFeatures ["Shared Pathological Features"] TA["Tau Protein Misfolding"] PH["Hyperphosphorylation"] AG["Aggregation into Fibrils"] NL["Neuronal Loss"] end TA --> PH --> AG --> NL AD --> TA CBD --> TA PSP --> TA FTLD --> TA

Tau Isoforms and Biochemistry

Isoform Composition

The tau protein exists in six isoforms in the adult human brain, generated by alternative splicing of exons 2, 3, and 10 in the [MAPT](/genes/mapt) gene. The key distinction is between three-repeat (3R) and four-repeat (4R) tau isoforms, determined by the inclusion or exclusion of exon 10[@wang2016].

...

Tauopathy Comparison Matrix

Overview

This page provides a comprehensive comparative analysis of the major tauopathies—Alzheimer's Disease (AD), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), and Frontotemporal Lobar Degeneration with tau pathology (FTLD-tau). These disorders share the common feature of abnormal tau protein accumulation but differ significantly in their clinical presentations, anatomical distributions, tau isoforms involved, and genetic risk factors[@goedert2022].

Mermaid diagram (expand to render)

Tau Isoforms and Biochemistry

Isoform Composition

The tau protein exists in six isoforms in the adult human brain, generated by alternative splicing of exons 2, 3, and 10 in the [MAPT](/genes/mapt) gene. The key distinction is between three-repeat (3R) and four-repeat (4R) tau isoforms, determined by the inclusion or exclusion of exon 10[@wang2016].

| Disease | Primary Tau Isoform | 3R:4R Ratio | Key Distinction |
|---------|-------------------|--------------|-----------------|
| Alzheimer's Disease | Mixed 3R + 4R | 1:1 | Both 3R and 4R tau in NFTs |
| CBD | 4R tau | 0:1 | Exclusively 4R tau |
| PSP | 4R tau | 0:1 | Exclusively 4R tau |
| FTLD-tau | Variable (mutation-dependent) | Variable | Depends on MAPT mutation |

Tau Filament Structures (Cryo-EM)

Recent cryo-electron microscopy studies have revealed distinct tau filament folds in each tauopathy, supporting the tau strain hypothesis[@fitzpatrick2017]:

| Disease | Filament Type | Structural Features |
|---------|--------------|---------------------|
| AD | Paired Helical Filaments (PHFs) | Classic helical structure, cross-β sheet |
| CBD | CBD Fold | Distinct helical filament architecture |
| PSP | PSP Fold (Globose NFTs) | 4R tau filaments, compact tangles |
| FTLD-tau | Variable | Depends on underlying mutation |

Post-Translational Modifications

| Modification | AD | CBD | PSP | FTLD-tau |
|--------------|-----|-----|-----|----------|
| Hyperphosphorylation | +++ | +++ | +++ | ++ |
| Acetylation | ++ | + | + | ++ |
| Truncation | ++ | + | + | ++ |
| Glycation | + | - | - | + |
| Ubiquitination | ++ | + | + | ++ |

Affected Brain Regions

Regional Distribution

| Brain Region | AD | CBD | PSP | FTLD-tau |
|--------------|-----|-----|-----|----------|
| Frontal Cortex | Late (neocortex) | ++ (early) | + (premotor) | +++ (early) |
| Parietal Cortex | Late | ++ | - | ++ |
| Temporal Cortex | Early (entorhinal) | + | - | ++ |
| Occipital Cortex | Late | - | - | + |
| Hippocampus | +++ (early) | - | - | + |
| Basal Ganglia | + | +++ | +++ | ++ |
| Substantia Nigra | + | +++ | +++ | + |
| Brainstem | + (later) | + | +++ | + |
| Cerebellum | - | + (dentate nucleus) | + (dentate) | - |

Neuroanatomical Progression Patterns

Alzheimer's Disease:

Braak stages I-II: Transentorhinal cortex (preclinical)
Braak stages III-IV: Limbic system (amnesitic MCI)
Braak stages V-VI: Isocortex (severe dementia)

Corticobasal Degeneration:

Motor and premotor cortex (early)
Basal ganglia (substantia nigra, globus pallidus)
Brainstem nuclei

Progressive Supranuclear Palsy:

Substantia nigra (early)
Globus pallidus
Brainstem (red nucleus, superior colliculus)
Frontal eye fields

FTLD-tau:

Frontal and anterior temporal lobes (early)
Amygdala and basal forebrain
Variable subcortical involvement

Mermaid diagram (expand to render)

Clinical Features

Core Diagnostic Symptoms

| Feature | AD | CBD | PSP | FTLD-tau |
|---------|-----|-----|-----|----------|
| Cognitive Decline | ++ (memory prominent) | ++ (executive) | + (executive) | +++ (executive/social) |
| Motor Symptoms | + (late) | +++ (asymmetric) | +++ (akinesia) | + (if present) |
| Eye Movement | - | - | +++ (vertical gaze palsy) | - |
| Postural Instability | - | ++ | +++ (falls early) | - |
| Language | + (anomia) | + | - | +++ (aphasia) |
| Behavior | + (late) | + | + | +++ (early) |
| Asymmetry | - | +++ | - | -/+ |

Disease-Specific Hallmarks

Alzheimer's Disease:

Progressive episodic memory loss
Anterograde amnesia
Word-finding difficulties (anomia)
Visuospatial impairment (later)
Behavioral changes in moderate to severe stages

Corticobasal Degeneration:

Asymmetric parkinsonism
Apraxia (especiallyideomotor)
Cortical sensory loss
Alien limb phenomenon
Myoclonus (sometimes)

Progressive Supranuclear Palsy:

Vertical supranuclear gaze palsy (downward > upward)
Early postural instability with falls
Akinesia and bradykinesia
Axial rigidity
Dysarthria and dysphagia

FTLD-tau:

Behavioral variant: Disinhibition, apathy, compulsions
Primary progressive aphasia: Nonfluent or semantic
Executive dysfunction
Relative memory preservation early

Clinical Progression

| Metric | AD | CBD | PSP | FTLD-tau |
|--------|-----|-----|-----|----------|
| Typical Onset (years) | 65-80 | 50-70 | 60-70 | 45-65 |
| Disease Duration (years) | 8-15 | 5-10 | 5-10 | 6-12 |
| Survival from Onset | 8-12 years | 6-8 years | 5-7 years | 6-11 years |

Genetic Risk Factors

Gene Associations

| Gene | AD | CBD | PSP | FTLD-tau |
|------|-----|-----|-----|----------|
| MAPT | Risk (H1 haplotype) | ++ (H1) | ++ (H1) | ++ (mutations) |
| APOE | ++ (ε4 risk) | - | - | - |
| GRN | - | + | - | ++ (mutations) |
| LRRK2 | + (risk) | + | + (risk) | - |
| C9orf72 | - | - | - | ++ (expansion) |
| TARDBP | - | - | - | + |
| VCP | - | - | - | + |

MAPT H1 Haplotype

The H1 haplotype of [MAPT](/genes/mapt) is a significant risk factor for sporadic tauopathies[@connor2004]:

H1/H1 genotype: Increases risk for CBD, PSP, and AD
H1/H2 genotype: May be protective
Odds ratio for PSP: ~4-5
Odds ratio for CBD: ~3-4

FTLD-tau Specific Mutations

Specific [MAPT](/genes/mapt) mutations cause familial FTLD-tau:

| Mutation | Exon | Effect | Phenotype |
|----------|------|--------|-----------|
| P301L | 10 | Increased aggregation | CBD/PSP/FTD |
| P301S | 10 | Increased aggregation | CBD/FTD |
| V337M | 12 | Altered splicing | FTD |
| R406W | 13 | Reduced binding | FTD/AD-like |

Therapeutic Approaches

Current Treatment Strategies

| Approach | AD | CBD | PSP | FTLD-tau |
|----------|-----|-----|-----|----------|
| Symptomatic | Donepezil, memantine | Limited | Limited | Limited |
| Tau Aggregation Inhibitors | In trials | Preclinical | Preclinical | Preclinical |
| Immunotherapy | Phase 2/3 | Preclinical | Preclinical | Preclinical |
| Kinase Inhibitors | GSK-3β in trials | Preclinical | Preclinical | Preclinical |

Clinical Trials Landscape

Active/Recent Anti-Tau Trials for AD:

Gosuranemab (Biogen) — Phase II completed
Semorinemab (Roche) — Phase II
Tilavonemab (AbbVie) — Phase II
JNJ-63761257 (Janssen) — Phase I

Disease-Modifying Approaches:

Microtubule stabilizers (e.g., davunetide)
Tau antisense oligonucleotides
Gene therapy approaches

Symptomatic Management

| Symptom | AD | CBD | PSP | FTLD-tau |
|---------|-----|-----|-----|----------|
| Cognitive | Cholinesterase inhibitors | None | None | None |
| Motor | None | Dopamine agonists | Limited | None |
| Behavioral | Antidepressants | Antidepressants | Antidepressants | SSRIs |
| Sleep | Melatonin | Clonazepam | Melatonin | Varies |

Biomarkers

CSF Biomarkers

| Marker | AD | CBD | PSP | FTLD-tau |
|--------|-----|-----|-----|----------|
| Total tau | Elevated ++ | Normal/+ | Normal/+ | Normal/+ |
| p-tau181 | Elevated +++ | Normal/+ | Normal/+ | Normal/+ |
| p-tau217 | Elevated +++ | Normal | Normal | Normal |
| p-tau231 | Elevated ++ | Normal | Normal | Normal |
| NfL | Elevated ++ | Elevated ++ | Elevated ++ | Elevated + |

PET Imaging

| Tracer | Target | AD | CBD | PSP | FTLD-tau |
|--------|--------|-----|-----|-----|----------|
| ^18F-AV-1451 | PHF tau | ++ | + | + | + |
| ^18F-MK-6240 | PHF tau | ++ | + | + | + |
| ^18F-GT1 | 4R tau | - | ++ | ++ | Variable |
| ^11C-PBB3 | All tau | ++ | ++ | ++ | ++ |

Differential Diagnosis

Key Distinguishing Features

| Feature | AD | CBD | PSP | FTLD-tau |
|---------|-----|-----|-----|----------|
| Memory loss | First/dominant | Late/mild | Late/mild | Late/mild |
| Motor onset | Late | Early (asymmetric) | Early (symmetric) | Variable |
| Eye movements | Normal | Normal | VSGP | Normal |
| Speech | Anomia | Dysarthria | Hypophonia | Aphasia |
| Personality | Preserved | Preserved | Apathy | Disinhibited |

Clinical Criteria

NINDS-SPSP Criteria for PSP:

Vertical supranuclear gaze palsy
Postural instability with falls within first year
Akinesia with bradykinesia

Core Clinical Features for CBD:

Asymmetric parkinsonism
Apraxia
Cortical sensory loss
Alien limb

Cross-References

[Tau Protein](/proteins/tau) — Main tau protein page
[4R Tau](/proteins/4r-tau) — Four-repeat tau isoform
[3R Tau](/proteins/3r-tau) — Three-repeat tau isoform
[Phospho-Tau](/proteins/phospho-tau) — Phosphorylated tau
[p-Tau181](/proteins/p-tau181-protein) — AD biomarker
[p-Tau217](/proteins/p-tau217-protein) — AD biomarker
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Corticobasal Degeneration](/diseases/corticobasal-degeneration)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[4R Tauopathies Genetics](/diseases/4r-tauopathies-genetics)
[MAPT Gene](/genes/mapt)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Tau Pathology](/mechanisms/tau-pathology)

References

[Goedert M, et al., Tauopathies: Update and perspective. Brain Res Bull. 2022;182:34-48 (2022)](https://pubmed.ncbi.nlm.nih.gov/35151579/)

[Unknown, Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5-21 (2016)](https://pubmed.ncbi.nlm.nih.gov/26634968/)

[Fitzpatrick M, et al., Cryo-EM structures of tau filaments from Alzheimer's disease brain. Nature. 2017;547(7662):185-190 (2017)](https://pubmed.ncbi.nlm.nih.gov/28678775/)

[Connor L, et al., MAPT haplotype H1 is associated with increased risk of PSP and CBD. Neurology. 2004;63(1):166-167 (2004)](https://pubmed.ncbi.nlm.nih.gov/15249631/)

[Williams DR, et al., Characteristics of two distinct clinical phenotypes in PSP. Brain. 2005;128(Pt 6):1247-1258 (2005)](https://pubmed.ncbi.nlm.nih.gov/15737937/)

[Litvan I, et al., Accuracy of clinical diagnosis of progressive supranuclear palsy. Neurology. 1996;46(4):922-930 (1996)](https://pubmed.ncbi.nlm.nih.gov/8780075/)

[Alexander SK, et al., Pathological relationships between CBD and PSP. Brain. 2014;137(Pt 7):1927-1938 (2014)](https://pubmed.ncbi.nlm.nih.gov/24836286/)

[Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2011;12(2):95-107 (2011)](https://pubmed.ncbi.nlm.nih.gov/21252998/)

[Choi W, et al., Tau PET imaging in atypical parkinsonism. Mov Disord. 2022;37(2):288-299 (2022)](https://pubmed.ncbi.nlm.nih.gov/34751467/)

[Hogan DB, et al., The progression of FTLD. Nat Rev Neurol. 2023;19(10):585-598 (2023)](https://pubmed.ncbi.nlm.nih.gov/37644123/)

📖 View canonical wiki page →

Related Entities

diseases-tauopathy-comparison

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-tauopathy-comparison
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8cc5f13f8163
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-tauopathy-comparison'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

26

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Tauopathy Comparison Matrix

Tauopathy Comparison Matrix

Overview

Tau Isoforms and Biochemistry

Isoform Composition

Tauopathy Comparison Matrix

Overview

Tau Isoforms and Biochemistry

Isoform Composition

Tau Filament Structures (Cryo-EM)

Post-Translational Modifications

Affected Brain Regions

Regional Distribution

Neuroanatomical Progression Patterns

Clinical Features

Core Diagnostic Symptoms

Disease-Specific Hallmarks

Clinical Progression

Genetic Risk Factors

Gene Associations

MAPT H1 Haplotype

FTLD-tau Specific Mutations

Therapeutic Approaches

Current Treatment Strategies

Clinical Trials Landscape

Symptomatic Management

Biomarkers

CSF Biomarkers

PET Imaging

Differential Diagnosis

Key Distinguishing Features

Clinical Criteria

Cross-References

References

💬 Discussion

📗 Cite This Artifact

Tauopathy Comparison Matrix

Tauopathy Comparison Matrix

Overview

Tau Isoforms and Biochemistry

Isoform Composition

Tauopathy Comparison Matrix

Overview

Tau Isoforms and Biochemistry

Isoform Composition

Tau Filament Structures (Cryo-EM)

Post-Translational Modifications

Affected Brain Regions

Regional Distribution

Neuroanatomical Progression Patterns

Clinical Features

Core Diagnostic Symptoms

Disease-Specific Hallmarks

Clinical Progression

Genetic Risk Factors

Gene Associations

MAPT H1 Haplotype

FTLD-tau Specific Mutations

Therapeutic Approaches

Current Treatment Strategies

Clinical Trials Landscape

Symptomatic Management

Biomarkers

CSF Biomarkers

PET Imaging

Differential Diagnosis

Key Distinguishing Features

Clinical Criteria

Cross-References

Related Pages

References

💬 Discussion